ArticleMethods in molecular biology (Clifton, N.J.)2026
Single-Cell RNA Sequencing of Pancreatic Circulating Tumor Cells.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most aggressive malignancies, characterized by poor prognosis and high metastatic potential. Circulating tumor cells (CTCs) are critical mediators of metastasis and hold promise as biomarkers for early detection and therapy monitoring. However, their extreme rarity and heterogeneity pose significant challenges for their enrichment and analysis. Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology to address these challenges by providing high-resolution insights into individual CTC biology.This chapter presents a comprehensive workflow for isolating and analyzing pancreatic cancer-derived CTCs using scRNA-seq. The protocol integrates size-based microfluidic enrichment, followed by negative selection via fluorescence-activated cell sorting (FACS), and concludes with single-cell transcriptome sequencing combined with target mutation detection. This method addresses critical purity and cell recovery limitations, allowing for the robust characterization of rare CTC populations. The insights gained from this workflow deepen our understanding of pancreatic cancer progression and facilitate the identification of novel therapeutic targets. By providing a practical example, this chapter serves as a valuable guide for researchers seeking to optimize single-cell sequencing techniques in their CTC studies.
Indexed as
Identifiers
42426462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.